CellCept - Mycophenolate mofetil

CellCept Mycophenolate mofetil Combantrin Pyrantel pamoate... 

Package insert. Cellcept (mycophenolate mofetil). Nutley, NJ, Roche Laboratories, March, 2003. 

CellCept (Mycophenolate mofetil). Roche Products Ltd. UK Summary of product characteristics, March 2006. 

Yocum D, Kremer J, Blackburn W, Caldwell J, Furst D, Nunez M, Zuzga J, Zeig S, Gutierrez M, Merrill J, Dumont E, B Leishman. Cellcept (mycophenolate mofetil - MMF) and methotrexate (MTX) safety and pharmacokinetic (PK) interaction study in rheumatoid arthritis patients./irt/rntisR/rewm (1999) 42 (9 Suppl), S83. 

Mycophenolate mofetil (CellCept) inhibits DNA and RNA synthesis and has been shown to have a specific lymphocyte antiproliferative effect. Although not FDA approved for this indication, oral mycophenolate mofetil appears effective in the treatment of moderate to severe plaque psoriasis. The usual dose is 500 mg orally four times a day, up to a maximum of 4 g/day. Common adverse effects include GI toxicity (diarrhea, nausea, vomiting), hematologic effects (anemia, neutropenia, thrombocytopenia), and viral and bacterial infections. Lymphoproliferative disease or lymphoma has been reported. 

Mycophenolate mofetil (MMF, CellCept) is an ester prodrug of mycophenolic acid (MPA), a Penicillium-de-rived immunosuppressive agent (see Chapter 57) that blocks de novo purine synthesis by noncompetitively inhibiting the enzyme inosine monophosphate dehydrogenase. MPA preferentially suppresses the proliferation of cells, such as T and B lymphocytes, that lack the purine salvage pathway and must synthesize de novo... 

Parenteral 5 mg/5 mL ampule for injection Mycophenolate mofetil (CellCept, Myfortic)... 

Formulation 250 mg capsules supplied in bottles of fOO and 500 500 mg tablets in bottles of 100 and 500 CellCept intravenous 20 ml, sterile vial containing 500 mg mycophenolate mofetil... 

Clinical Use. Mycophenolate mofetil (CellCept) is primarily used to prevent or treat organ rejection following cardiac and renal transplantation. This drug is typically combined with other immunosuppressants (cyclosporine, glucocorticoids) to provide optimal immunosuppression in patients receiving these transplant types.39,40,70 Mycophenolate mofetil may also be useful in suppressing the immune response associated with autoimmune conditions such as systemic lupus erythematosus.2... 

Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. Transplant Proc 1997 29(1—2) 334—336. 

SLE appears to be steroid responsive only in the early coiu se of the disease. Optic atrophy occiu s in untreated cases, with the development of permanent visual field defects. Therapy includes high-dose intravenous methyl-prednisolone, oral prednisone, or steroid-sparing medications such as mycophenolate mofetil (CellCept). A rheumatology referral is also advised. 

Behrend M. Mycophenolate mofetil Cellcept. Expert Opin. In-... 

Mycil chlorphenesin tolnafitate. mycophenolate mofetil [usan] (CellCept ) is converted in vivo to n cophenolic add, which has antimetabolite cytotoxic properties. It shows experimental activity as an ANTICANCER and ANTIVIRAL AGENT. It may be clinically useful in treating psoriasis and as an ANTU.EISHMANIAL. It shows IMMUNOSUPPRESSANT properties, and is used in the prophylaxis of acute kidney rejection, mycophenolic acid [ban, inn, usan] is usually... 

Synonym mycophenolate mofetil Trade names CellCept (Roche) Myfortic (Novartis) Indications Prophylaxis of organ rejection Category Immunosuppressant TNF inhibitor Half-life 18 hours... 

Mycophenolate mofetil (Cellcept) is the 2-morpholino-ethyl ester of mycophenolic acid (MPA). 

Mycophenolate mofetil (Cellcept) is an immunosuppressant approved for prophylaxis of organ rejection in patients with renal, cardiac, and hepatic transplants. Myco-phenolic acid, the active derivative of mycophenolate mofetil, inhibits the enzyme inosine monophosphatase dehydrogenase (IMPDH), thereby depleting guanosine nucleotides essential for DNA and RNA synthesis. Moreover, mycophenolic acid is a fivefold more potent inhibitor of the type 11 isoform of IMPDH found in activated B- and T-lymphocytes and thus functions as a specific inhibitor of T- and B-lymphocyte activation and proliferation. The drug also may enhance apoptosis. 

---